APP
PGNX

Avantax Planning Partners’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Avantax Planning Partners’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-322
Closed -$2K – 1380
2018
Q3 		$2K Buy
+322
New +$2.47K ﹤0.01% 1392
2018
Q2 		– Sell
-422
Closed -$3K – 1728
2018
Q1 		$3K Buy
+422
New +$2.81K ﹤0.01% 1560

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Avantax Planning Partners's PGNX Position: Q4 2018 in Review

Avantax Planning Partners sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2018, closing a stake of 322 shares — an estimated $2K sold.

Avantax Planning Partners first reported a position in PGNX in Q1 2018 and held it in 2 quarters. The position peaked at $3K in Q1 2018. 150 funds tracked by Wall St. Rank hold PGNX as of Q4 2018.

  • Avantax Planning Partners reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 322 Progenics Pharmaceuticals Inc shares in Q4 2018, an estimated $2K.
  • Avantax Planning Partners first reported a position in Progenics Pharmaceuticals Inc in Q1 2018 and held it in 2 quarters.
  • Avantax Planning Partners's Progenics Pharmaceuticals Inc position peaked at $3K in Q1 2018.
  • 150 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.